X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs UNICHEM LAB - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA UNICHEM LAB GLENMARK PHARMA/
UNICHEM LAB
 
P/E (TTM) x 19.1 282.1 6.8% View Chart
P/BV x 3.4 0.6 522.5% View Chart
Dividend Yield % 0.3 2.6 11.9%  

Financials

 GLENMARK PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
UNICHEM LAB
Mar-18
GLENMARK PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs930382 243.5%   
Low Rs517234 221.0%   
Sales per share (Unadj.) Rs322.6116.3 277.4%  
Earnings per share (Unadj.) Rs28.5-18.9 -150.6%  
Cash flow per share (Unadj.) Rs39.2-11.7 -333.8%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.31.6 17.0%  
Book value per share (Unadj.) Rs183.0381.0 48.0%  
Shares outstanding (eoy) m282.1770.34 401.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.22.6 84.7%   
Avg P/E ratio x25.4-16.3 -156.0%  
P/CF ratio (eoy) x18.5-26.2 -70.4%  
Price / Book Value ratio x4.00.8 489.2%  
Dividend payout %7.0-26.4 -26.6%   
Avg Mkt Cap Rs m204,20621,668 942.4%   
No. of employees `00013.72.3 601.6%   
Total wages/salary Rs m18,7182,006 932.9%   
Avg. sales/employee Rs Th6,636.83,587.8 185.0%   
Avg. wages/employee Rs Th1,364.7880.0 155.1%   
Avg. net profit/employee Rs Th586.1-583.7 -100.4%   
INCOME DATA
Net Sales Rs m91,0318,180 1,112.8%  
Other income Rs m914610 149.8%   
Total revenues Rs m91,9458,790 1,046.0%   
Gross profit Rs m16,154-1,320 -1,223.6%  
Depreciation Rs m3,019505 597.7%   
Interest Rs m2,85680 3,565.2%   
Profit before tax Rs m11,193-1,295 -864.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,15533 9,439.3%   
Profit after tax Rs m8,039-1,331 -604.0%  
Gross profit margin %17.7-16.1 -110.0%  
Effective tax rate %28.2-2.6 -1,092.3%   
Net profit margin %8.8-16.3 -54.3%  
BALANCE SHEET DATA
Current assets Rs m69,88723,318 299.7%   
Current liabilities Rs m32,8794,635 709.3%   
Net working cap to sales %40.7228.4 17.8%  
Current ratio x2.15.0 42.3%  
Inventory Days Days81122 66.9%  
Debtors Days Days93121 77.0%  
Net fixed assets Rs m28,8928,163 353.9%   
Share capital Rs m282141 200.6%   
"Free" reserves Rs m51,35326,660 192.6%   
Net worth Rs m51,63526,801 192.7%   
Long term debt Rs m41,4183 1,255,084.8%   
Total assets Rs m125,95431,890 395.0%  
Interest coverage x4.9-15.2 -32.4%   
Debt to equity ratio x0.80 651,446.3%  
Sales to assets ratio x0.70.3 281.8%   
Return on assets %8.6-3.9 -220.5%  
Return on equity %15.6-5.0 -313.5%  
Return on capital %15.1-4.5 -332.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,3174,356 833.6%   
Fx outflow Rs m9,7200-   
Net fx Rs m26,5984,356 610.5%   
CASH FLOW
From Operations Rs m16,481-1,123 -1,467.0%  
From Investments Rs m-10,13316,487 -61.5%  
From Financial Activity Rs m-4,685-8,811 53.2%  
Net Cashflow Rs m1,7706,552 27.0%  

Share Holding

Indian Promoters % 48.3 50.1 96.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 15.1 45.7%  
FIIs % 34.4 3.0 1,146.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 31.7 33.1%  
Shareholders   56,727 20,176 281.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ELDER PHARMA  TTK HEALTHCARE  ORCHID PHARMA LTD  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Mar 22, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS